Mark Lampert‘s Biotechnology Value Fund LP recently filed a 13G with the US SEC to report lowering its stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) to 399,433 shares, which amass 2.1% of the float. The stake was lowered from 2.14 million shares which Biotechnology Value Fund previously held, which accounted for 11.4% of the company’s outstanding stock, as per its previous 13G filing on the company.
Tobira Therapeutics, formerly Regado Biosciences, is a biopharmaceutical company that develops therapies to help treat patients who suffer from liver disease, inflammation fibrosis, and HIV. On September 20, Tobira signed an agreement with Allergan plc (NYSE:AGN) to be acquired by the company for a total sum of around $1.7 billion. Year-to-date, Tobira’s stock is up by a massive 293.03%.
Seven of the hedge funds that we track were long Tobira Therapeutics Inc. (NASDAQ:TBRA) on June 30, down by two during the second quarter. Lampert’s fund had the largest position among the funds in our database, valued at $15.74 million, while Paul Marshall and Ian Wace’s Marshall Wace LLP, and Israel Englander’s Millennium Management also held positions worth more than a million dollars. Brian Ashford-Russell and Tim Woolley’s Polar Capital sold off its 50,000-share stake in the second quarter.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Biotechnology Value Trading Fund OS||0||33,627||0||33,627||33,627||Less than 1%|
|BVF Partners OS Ltd||0||33,627||0||33,627||33,627||Less than 1%|
|Mark N. Lampert||0||399,433||0||399,433||399,433||2.1%|
Page 1 of 11 – SEC Filing
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
Tobira Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
88883P 10 1
September 20, 2016
(Date of Event Which Requires Filing of this Statement)